[go: up one dir, main page]

WO2009002418A3 - T-cell peptide epitopes from carcinoembryonic antigen, immunogenic analogs, and uses thereof - Google Patents

T-cell peptide epitopes from carcinoembryonic antigen, immunogenic analogs, and uses thereof Download PDF

Info

Publication number
WO2009002418A3
WO2009002418A3 PCT/US2008/007551 US2008007551W WO2009002418A3 WO 2009002418 A3 WO2009002418 A3 WO 2009002418A3 US 2008007551 W US2008007551 W US 2008007551W WO 2009002418 A3 WO2009002418 A3 WO 2009002418A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogs
cea
disclosed
carcinoembryonic antigen
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/007551
Other languages
French (fr)
Other versions
WO2009002418A2 (en
Inventor
Luigi Aurisicchio
Elisa Scarselli
Nicola La Monica
Gennaro Ciliberto
Arthur Fridman
Irene Pak
Ansuman Bagchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Merck and Co Inc
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA, Merck and Co Inc filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Publication of WO2009002418A2 publication Critical patent/WO2009002418A2/en
Anticipated expiration legal-status Critical
Publication of WO2009002418A3 publication Critical patent/WO2009002418A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides vaccines and pharmaceutical compositions which can, when administered to a patient, elicit an immune response to the carcinoembryonic antigen (CEA). Immunogenic peptide epitopes of human CEA are provided, as well as immunogenic peptide analogs which can induce an immune response cross-reactive against CEA which response is superior in quality to that induced by the corresponding wild-type epitope. Also disclosed herein are pharmaceutical compositions and vaccines comprising one or more of said peptides and analogs for prophylaxis and/or treatment of cancer. This invention further provides polynucleotides encoding at least one of the CEA analogs described herein, and vectors and host cells comprising said polynucleotides. Methods of inducing an immune response in a patient, in addition to methods of treatment using the immunogenic peptides, peptide analogs and polynucleotides disclosed herein are also disclosed.
PCT/US2008/007551 2007-06-21 2008-06-17 T-cell peptide epitopes from carcinoembryonic antigen, immunogenic analogs, and uses thereof Ceased WO2009002418A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93697307P 2007-06-21 2007-06-21
US60/936,973 2007-06-21

Publications (2)

Publication Number Publication Date
WO2009002418A2 WO2009002418A2 (en) 2008-12-31
WO2009002418A3 true WO2009002418A3 (en) 2010-01-07

Family

ID=40186204

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/007551 Ceased WO2009002418A2 (en) 2007-06-21 2008-06-17 T-cell peptide epitopes from carcinoembryonic antigen, immunogenic analogs, and uses thereof

Country Status (1)

Country Link
WO (1) WO2009002418A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140634A2 (en) 2010-05-11 2011-11-17 Governing Council Of The University Of Toronto The n-domain of carcinoembryonic antigen and compositions, methods and uses thereof
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
EP3177718B1 (en) 2014-07-30 2022-03-16 President and Fellows of Harvard College Cas9 proteins including ligand-dependent inteins
WO2017070633A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Evolved cas9 proteins for gene editing
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
KR20190123328A (en) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Cancer vaccine
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
JP2020510439A (en) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ Base-editing factor from cytosine to guanine
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP3797160A1 (en) 2018-05-23 2021-03-31 The Broad Institute Inc. Base editors and uses thereof
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
SG11202109882VA (en) 2019-03-19 2021-10-28 Broad Inst Inc Methods and compositions for editing nucleotide sequences
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
KR20230019843A (en) 2020-05-08 2023-02-09 더 브로드 인스티튜트, 인코퍼레이티드 Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CN116710115A (en) 2020-11-20 2023-09-05 思维疗法股份有限公司 Compositions and methods for optimized peptide vaccines
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070055049A1 (en) * 1992-08-07 2007-03-08 Grey Howard M HLA binding motifs and peptides and their uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070055049A1 (en) * 1992-08-07 2007-03-08 Grey Howard M HLA binding motifs and peptides and their uses

Also Published As

Publication number Publication date
WO2009002418A2 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
WO2009002418A3 (en) T-cell peptide epitopes from carcinoembryonic antigen, immunogenic analogs, and uses thereof
Goel et al. Intradermal immunization with outer membrane protein 25 protects Balb/c mice from virulent B. abortus 544
WO2007022151A3 (en) Immunization of avians by administration of non-replicating vectored vaccines
WO2006036550A3 (en) Listeria-based and llo-based vaccines
MX364689B (en) Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type.
WO2009015842A3 (en) Novel immunogenic epitopes for immunotherapy
RU2014144133A (en) PROSTAT-ASSOCIATED ANTIGENS AND IMMUNOTHERAPEUTIC SCHEMES BASED ON VACCINES
ZA200708635B (en) Peptide conjugate compositions and methods for the prevention and treatment of alzheimers disease
MX2009009342A (en) Novel method and compositions.
GB2434367A (en) Improved vaccines
JP2016539946A5 (en)
Flach et al. A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori
EA201290675A1 (en) VACCINE VECTORS AND METHODS OF STRENGTHENING IMMUNE RESPONSES
MX2021002449A (en) Peptide vaccines.
MX355054B (en) Hig2 and urlc10 epitope peptide and vaccines containing the same.
WO2021055580A3 (en) An anaplastic lymphoma kinase (alk) cancer vaccine and methods of use
WO2006138568A3 (en) Multivalent entrain-and-amplify immunotherapeutics for carcinoma
JP2015529677A5 (en)
WO2013171661A3 (en) Adjuvant formulations and methods
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
WO2009042538A3 (en) Immunogenic proteins from genome-derived outer membrane of leptospira and compositions and methods based thereon
WO2008082719A3 (en) Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
WO2007146359A3 (en) Sea lice antigen vaccines
TNSN08184A1 (en) Chimeric antigens and vaccines
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08768548

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08768548

Country of ref document: EP

Kind code of ref document: A2